Roitman, S., Greenfield, D
In a press release from November 2023, the company announced that they were bringing lawsuits against two compounding pharmacies for selling adulterated and misbranded compounded drugs claiming to contain semaglutide. In a statement to Healthline, a Novo Nordisk representative said: To date, Novo Nordisk has filed a total of 12 legal actions against medical spas, weight loss or medical clinics, and compounding pharmacies to cease and desist from false advertising, trademark infringement and unlawful sales of non-FDA approved compounded products claiming to contain semaglutide
As highlighted earlier, the Phase 2 clinical trials demonstrated unprecedented mean body weight reductions, indicating its superior efficacy compared to existing monotherapies
If the moles are numerous or involve the head or spine, consultation with a neurologist may be suggested
Discussion Glucagon-like peptide 1 agonists have been used for glycemic control in patients with type 2 diabetes 1 for over 12 years and have proven to have a very good safety profile